ENO1 and Patent ductus arteriosus: For this reason, we are investigating—in PDA patients—the potential effect of CTX in inducing novel TAAs or in enhancing the antigenicity of the already established TAAs, such as ENO1, to enhance the positive effect of DNA vaccination with the combination of CTX treatment.